Do you treat retroperitoneal sarcomas with a boost to the rind (or suspected close surgical margin)?
If so, what patients do you select for the boost? And what data do you give to adequately satisfy the insurance review and win approval?
Answer from: Radiation Oncologist at Academic Institution
I have done this for retroperitoneal sarcomas that have contact with structures that represent challenges for my surgical colleagues (e.g. vessels, spine). This was initially inspired by the publication by the group from UAB who delivered 45 Gy in 25 fractions to the whole target and then boosted th...